Compare MAN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | AMLX |
|---|---|---|
| Founded | 1948 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1988 | 2022 |
| Metric | MAN | AMLX |
|---|---|---|
| Price | $30.37 | $14.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $39.50 | $17.43 |
| AVG Volume (30 Days) | 836.7K | ★ 1.8M |
| Earning Date | 01-29-2026 | 03-03-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,643,700,000.00 | N/A |
| Revenue This Year | $1.15 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.14 | $2.60 |
| 52 Week High | $63.35 | $17.49 |
| Indicator | MAN | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 58.61 |
| Support Level | $28.83 | $12.08 |
| Resistance Level | $31.54 | $17.49 |
| Average True Range (ATR) | 1.17 | 1.02 |
| MACD | -0.01 | 0.38 |
| Stochastic Oscillator | 53.25 | 61.90 |
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that include Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives the maximum of the company's revenue. The company derives maximum geographical revenue from the Southern European region.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.